mRNAbased

Collaboration will combine Moderna’s mRNA technology with CytomX’s Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35…

Researchers around the world have been working for years on developing vaccines against different types of cancer, but without much success. Now, Tufts School of Engineering researchers…

The trial found that the vaccines were safe and did not cause unexpected adverse events in a group of patients with various cancers, neurological, and rheumatological conditions that are…

The trial found that the vaccines were safe and did not cause unexpected adverse events in a group of patients with various cancers, neurological, and rheumatological conditions that are…

Pfizer and Codex DNA agree to strategic, multiyear, early access research collaboration, leveraging Codex DNA’s novel enzymatic DNA synthesis (EDS) technologyPfizer’s successful development…

Gennova is the first Indian pharma company to develop an indigenous mRNA platform and the company has been working on this platform for the past four years.Gennova Biopharmaceuticals, a…

The company is awaiting regulatory approvals for its mRNA vaccine for Covid-19. (Representational image)India’s first mRNA-based Covid-19 vaccine, from Gennova Biopharma, a subsidiary of…

The study analyzed 22 potential allergic reactions to the first 39,000 doses of Pfizer and Moderna COVID-19 vaccines given to health care providers at Stanford soon after the vaccines…

Allergic reactions to the new mRNA-based COVID-19 vaccines are rare, typically mild and treatable, and they should not deter people from becoming vaccinated, according to research from the…